Medidata Solutions upgraded to Buy from Neutral at B. Riley B. Riley upgraded Medidata Solutions to Buy citing yesterday's pullback in shares. The firm lowered its price target for shares to $49 from $53.
Medidata Solutions COO appointment positive, says JPMorgan JPMorgan views Medidata's addition of Michael Capone in the newly created role of COO as a positive, as Capone should be able to help the company scale and should free up the company's CEO and President to focus on strategy and big deals. The firm maintains its Overweight rating on the stock.
Medidata Solutions initiated with an Overweight at JPMorgan JPMorgan believes software dedicated to the clinical trial process will be in high demand for years to come. The firm started shares of Medidata Solutions with an Overweight rating and $60 price target.